Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial

已完结 10 由达姆发布于 2025/12/23 8:07:40

DOI:10.1016/s2468-1253(25)00296-1
作者：Vipul Jairath, Silvio Danese, Geert R D’Haens, Brian G Feagan, Laurent Peyrin-Biroulet, Bruce E Sands, Ingrid Gaemers, Matt Westfall, Allyson Q Terry, Kevin J Roberts, Sara Barbat, Pamela Wedel, Jacq
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundSOR102 is an oral bispecific antibody comprised of single domain antibodies targeting TNF and interleukin (IL)-23p19. We aimed to assess the safety, pharmacokinetics, clinical, and

应助信息

9小时前

biofresh

9375d0dadf9411f0baa434735aa3bc31.pdf 已采纳

9小时前

Book学术机器人

2025/12/23 8:07:40 未找到该文献，机器人已退出，请等待人工下载

2025/12/23 8:07:40 Book学术AI机器人收到请求，开始寻找文献

2025/12/23 8:07:40 已向机器人发送请求

9小时前

达姆发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierPolyurethane degradation by extracellular urethanase producing bacterial isolate Moraxella catarrhalis strain BMPPS3